CARBIDOPA

Search structure
Trade Names:
Synonyms:
Status: Approved (1975)
Entry Type: Small molecule
Molecule Category: Parent
UNII: MNX7R8C5VO

Structure
InChI Key TZFNLOMSOLWIDK-JTQLQIEISA-N
Smile C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
InChI
InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C10H14N2O4
Molecular Weight 226.23
AlogP -0.05
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 5.0
Number of Rotational Bond 4.0
Polar Surface Area 115.81
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 16.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR DOPA decarboxylase inhibitor PubMed DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Epigenetic regulator Eraser Lysine demethylase Jumonji domain-containing
- - - 1980 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 113

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Amblyopia 3 D000550 ClinicalTrials
Stroke 3 D020521 ClinicalTrials
Dysautonomia, Familial 3 D004402 ClinicalTrials
Spinal Cord Injuries 2 D013119 ClinicalTrials
Back Pain 2 D001416 ClinicalTrials
Fibromyalgia 2 D005356 ClinicalTrials
Schizophrenia 2 D012559 ClinicalTrials
Macular Degeneration 2 D008268 ClinicalTrials
Cocaine-Related Disorders 2 D019970 ClinicalTrials
Multiple Sclerosis 2 D009103 ClinicalTrials
Attention Deficit Disorder with Hyperactivity 2 D001289 ClinicalTrials
Retinitis Pigmentosa 2 D012174 ClinicalTrials
Pain 2 D010146 ClinicalTrials
Albinism, Oculocutaneous 2 D016115 ClinicalTrials
Aphasia 2 D001037 ClinicalTrials
Hypertension 1 D006973 ClinicalTrials
Asthma 1 D001249 ClinicalTrials
Angelman Syndrome 1 D017204 ClinicalTrials
Tobacco Use Disorder 1 D014029 ClinicalTrials
Amyotrophic Lateral Sclerosis 1 D000690 ClinicalTrials
Hypotension, Orthostatic 1 D007024 ClinicalTrials

Related Entries

MCS

Mixture
Mixture

Side Effects from Label

Side effects Relative Frequency (%) Labels
Nervous system disorders Dyskinesia 16.5
Nervous system disorders Dyskinesia 12.2
Gastrointestinal disorders Nausea 5.7
Gastrointestinal disorders Nausea 5.5
Psychiatric disorders Hallucination 3.9
Nervous system disorders Confusional state 3.7
General disorders and administration site conditions Feeling abnormal 3.7
Psychiatric disorders Hallucination 3.2
Cardiac disorders Dizziness 2.9
Nervous system disorders Confusional state 2.3
Cardiac disorders Dizziness 2.3
General disorders and administration site conditions Feeling abnormal 2.3
Infections and infestations Urinary tract infection 2.3
Psychiatric disorders Depression 2.2
Infections and infestations Urinary tract infection 2.2
Nervous system disorders Headache 2.0
Nervous system disorders Headache 1.9
Gastrointestinal disorders Vomiting 1.9
Infections and infestations Upper respiratory tract infection 1.8
Gastrointestinal disorders Vomiting 1.8
Musculoskeletal and connective tissue disorders Back pain 1.6
Cardiac disorders Dyspnoea 1.6
Gastrointestinal disorders Constipation 1.5
Gastrointestinal disorders Dry mouth 1.4
Psychiatric disorders Depression 1.3
General disorders and administration site conditions Decreased appetite 1.2
Gastrointestinal disorders Diarrhoea 1.2
Nervous system disorders Insomnia 1.2
General disorders and administration site conditions Decreased appetite 1.1
Gastrointestinal disorders Dry mouth 1.1
Gastrointestinal disorders Dyspepsia 1.1
Nervous system disorders Orthostatic hypotension 1.1
Nervous system disorders Paraesthesia 1.1
Renal and urinary disorders Pollakiuria 1.1
Cardiac disorders Chest pain 1.0
Nervous system disorders Insomnia 1.0
Musculoskeletal and connective tissue disorders Muscle spasms 1.0
Musculoskeletal and connective tissue disorders Musculoskeletal pain 1.0
Nervous system disorders Orthostatic hypotension 1.0
Infections and infestations Upper respiratory tract infection 1.0
Cardiac disorders Chest pain 0.8
Musculoskeletal and connective tissue disorders Muscle spasms 0.8
Nervous system disorders Paraesthesia 0.8
Renal and urinary disorders Pollakiuria 0.8
Musculoskeletal and connective tissue disorders Back pain 0.6
Gastrointestinal disorders Diarrhoea 0.6
Gastrointestinal disorders Dyspepsia 0.6
Musculoskeletal and connective tissue disorders Musculoskeletal pain 0.6
Cardiac disorders Dyspnoea 0.4
Gastrointestinal disorders Constipation 0.2

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
17.9
Nervous system disorders
16.16
Psychiatric disorders
13.54
Gastrointestinal disorders
13.1
Injury, poisoning and procedural complications
6.55
Cardiac disorders
5.68
Vascular disorders
4.37
Musculoskeletal and connective tissue disorders
3.93
Investigations
3.49
Respiratory, thoracic and mediastinal disorders
3.49
Metabolism and nutrition disorders
3.06
Infections and infestations
2.18

Cross References

Resources Reference
ChEBI 3395
ChEMBL CHEMBL1200748
FDA SRS MNX7R8C5VO
SureChEMBL SCHEMBL1217887
ChEBI 39585
ChEMBL CHEMBL1201236
DrugBank DB00190
DrugCentral 496
EPA CompTox DTXSID4022735
FDA SRS KR87B45RGH
Human Metabolome Database HMDB0014336
Guide to Pharmacology 5159
PDB 142
PharmGKB PA448794
SureChEMBL SCHEMBL35084
ZINC ZINC000019168887
CONTENTS